More on BBIO
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $25.90 |
|
|||
| Open | $25.69 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $26.46 | ||||
| Day Low | $25.69 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 1,743,211 | ||||
- BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions
- Oppenheimer Starts BridgeBio Pharma (BBIO) at Perform
- H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO)
- BMO Capital Reiterates Market Perform Rating on BridgeBio Pharma (BBIO)
- Piper Sandler Reiterates Overweight Rating on BridgeBio Pharma (BBIO)
- BridgeBio Pharma (BBIO) Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9
- BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
- H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO)
- BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitaliza
- BMO Capital Reiterates Market Perform Rating on BridgeBio Pharma (BBIO)
Entities mentioned with BBIO
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- Goldman Sachs | View Related Stories »
- S3 | View Related Stories »
- Raymond James | View Related Stories »
- Maynard Um | View Related Stories »
- Show More...
